This study is designed to determine the safety and feasibility of using Cerebrolysin in treating primary intracerebral hemorrhage (ICH).
This is a multicenter, prospective, randomized, open-label, blinded end-point, phase IV parallel group study done in specialized stroke treatment centers in Poland. The study objective is to evaluate if a 14-day cerebrolysin treatment initiated within 6 hours of onset of primary lobar hemorrhage in addition to the standard of care that includes early intensive rehabilitation is safe and feasible, affects hematoma growth and improves the outcome.
This study is designed to assess the early effect of using Cerebrolysin in patients after ICH, therefore 3 months of follow-up has been chosen. Patients will receive 50 ml of Cerebrolysin once daily until day 14. Subjects will be evaluated on Day 1 (baseline), Day 2, Day 7, Day 30 and Day 90.
Enrollment to the study is expected to reach 30 subjects in 12 months. The study should be completed within 15 months (the end of study).
The primary outcome measure will be change from baseline in functional independence (mRS 0-2) at Day 90 following stroke onset. The safety outcome will be the number of serious adverse events until Day 30.

开始日期2025-10-01

申办/合作机构-

NCT07043686

/ RecruitingN/AIIT

Effect of Cerebrolysin on Early Rehabilitation After Ischemic Stroke at the Department of Vascular Neurology and Intensive Neurological Therapy (KOVNINT), University Medical Centre Ljubljana

The study evaluates the effect and safety of Cerebrolysin administered during early rehabilitation in patients with moderate neurological impairment after acute ischemic stroke, conducted at the Department of Vascular Neurology and Intensive Neurological Therapy, UMC Ljubljana.

开始日期2025-06-13

申办/合作机构

UMC Ljubljana

NCT06897176

/ Recruiting临床4期IIT

Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study

" This study aims to measure changes in language ability after adding cerebrolysin to standard treatment for non-fluent aphasia patients with post-stroke language impairment. The patients are divided into two groups: the experimental group, which receives a combination of standard treatment (speech therapy) and cerebrolysin, and the control group, which only receives standard treatment (speech therapy). By comparing the PK-WAB scores before and after drug administration, the study seeks to analyze the impact of cerebrolysin on language improvement. According to various stroke registries, 15-42% of patients in the subacute phase of stroke and 25-50% of patients with chronic stroke show symptoms of aphasia. Language therapy for stroke-related aphasia has become increasingly important due to its association with prolonged hospitalization, increased healthcare costs, mortality, and other negative prognostic factors .
After central nervous system damage such as stroke and traumatic brain injury, the administration of growth hormones and neurotrophic factors such as brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF) has been reported to influence nerve regeneration.
Cerebrolysin (EVER Neuro Pharma GmbH, AUSTRIA) is a multi-modal drug composed of low-molecular peptides and amino acids, which shows neuroprotective and neurotrophic effects similar to endogenous neurotrophic factors. Analysis of cerebrolysin using ELISA revealed that it contains CNTF, GDNF, IGF1, IGF2, and other factors structurally and functionally similar to neurotrophic factors (NTFs). Cerebrolysin activates the same PI3K/Akt pathway as BDNF, playing a crucial role in the growth, proliferation, differentiation, and migration of nerve cells, and promoting the maintenance, protection, and repair of neural networks. Additionally, it activates the SHH pathway, facilitating neuroplasticity and neurogenesis, thereby aiding the brain's self-repair process and functional recovery. Recent studies have shown that cerebrolysin reduces inflammation in the cerebral vasculature and improves the integrity of the blood-brain barrier by increasing tight junctions.
Cerebrolysin has shown excellent effects on motor function improvement in moderate-to-severe stroke patients in studies by Muresanu et al. 2016. and Chang et al. 2016. Based on these results, cerebrolysin has been included in stroke rehabilitation guidelines in Austria (2018), Germany (2020), Canada (2020), the European Neuroscience Society (2021), and the Korean Brain and Neurorehabilitation Society (2022). Furthermore, cerebrolysin has been included in the Canadian TBI guidelines for improving attention in patients with moderate-to-severe traumatic brain injury, and it is expected to be beneficial in the rehabilitation of both stroke and traumatic brain injury patients.
Although there is strong evidence that cerebrolysin improves motor function, attention, and consciousness levels after stroke or brain injury, its effect on language abilities remains unclear. Moreover, previous studies have limitations, including the use of the Western Aphasia Battery Test and heterogeneity in language assessments. Therefore, this study plans to conduct additional research using a well-designed, double-blind, placebo-controlled, randomized study to assess the effect of cerebrolysin on non-fluent aphasia, using a variety of evaluation tools to accurately measure improvements in language abilities."

开始日期2025-03-12

申办/合作机构

Yonsei University

100 项与脑蛋白水解物相关的临床结果

登录后查看更多信息

100 项与脑蛋白水解物相关的转化医学

登录后查看更多信息

100 项与脑蛋白水解物相关的专利（医药）

登录后查看更多信息

538

项与脑蛋白水解物相关的文献（医药）

2025-12-01·CURRENT ALLERGY AND ASTHMA REPORTS

Treatment of COVID-19 Associated Olfactory Dysfunction: A Systematic Review

Review

作者: Vanderbroek, Annabelle ; Moyaert, Mathilde ; Clijsters, Marnick ; Van Gerven, Laura ; Bischoff, Sabrina

PURPOSE OF REVIEW:

COVID -19 associated olfactory dysfunction is widespread, yet effective treatment strategies remain unclear. This article aims to provide a comprehensive systematic review of therapeutic approaches and offers evidence-based recommendations for their clinical application.

RECENT FINDINGS:

A living Cochrane review, with rigorous inclusion criteria, has so far included 2 studies with a low certainty of evidence. In this systematic review we list clinical data of 36 randomised controlled trials (RCTs) and non-randomised studies published between Jan 1, 2020 and Nov 19, 2023 regarding treatment options for COVID-19 associated olfactory dysfunction. Nine treatment groups were analysed, including olfactory training, local and systemic corticosteroids, platelet-rich plasma (PRP), calcium chelators, vitamin supplements including palmitoylethanolamide with luteolin, insulin, gabapentin and cerebrolysin. Primary objective was the effect of the studied treatments on the delta olfactory function score (OFS) for objective/psychophysical testing. Treatments such as PRP and calcium chelators demonstrated significant improvements on OFS, whereas olfactory training and corticosteroids did not show notable efficacy for COVID-19 associated olfactory dysfunction.

2025-10-01·International Journal of Stroke

C-REGS2—A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke

Article

作者: Roushdy, Tamer ; Do, Youngrok ; Vosko, Milan R ; Brainin, Michael ; Sanak, Daniel ; Bornstein, Natan M ; Vester, Johannes C ; Vatanagul, Jarungchai S

Background::

The main objective of the Cerebrolysin REGistry Study in Stroke 2 (C-REGS2) was to systematically record the routine clinical use of Cerebrolysin in patients with moderate ischemic stroke (IS) following the principles of a prospective controlled effectiveness study (CES) to compare its effectiveness in terms of functional recovery to patients treated with standard therapy alone.

Methods::

C-REGS2 used an open-label, prospective controlled comparative effectiveness design aligning with the Target Trial Emulation Framework (TTEF) and the GRACE principles for high-quality observational studies based on the principles of high-quality comparative effectiveness research (HQCER) to capture treatment effects in clinical practice. The study was conducted in 16 countries worldwide between April 2018 and April 2024. Moderate IS was defined as baseline NIH Stroke Scale (NIHSS) score 8–15. Treatment modalities and concomitant medications were according to local standards. The methodology included rigorous pre-specified analysis and tight risk-based centralized monitoring, to ensure minimal enrollment bias, maximize data quality and overall reliability of trial results. The compared patient groups were standardized using a restricted cohort design and non-parametric multilevel stratification following the Good Research for Comparative Effectiveness (GRACE) principles. The primary endpoint was ordinal analysis of the modified Rankin Scale (mRS) at 90 days after stroke onset. Secondary endpoints were the ordinal NIH Stroke Scale (NIHSS) at day 21 and 90 after stroke onset, the ordinal mRS at 21 days after IS, the proportion of patients with excellent recovery (mRS 0–1) as well as the proportion of patients with functional independence (mRS 0–2) at 90 days after stroke onset and the ordinal analysis of Montreal Cognitive Assessment (MoCA) scale at 90 days after IS.

Results::

Out of 1865 enrolled patients, the target population (TP) comprised 1769 patients (1021 Cerebrolysin-treated and 748 controls). The median NIHSS at baseline was 10.0. Median Cerebrolysin dose was 30 ml, median treatment duration was 10 days. Cerebrolysin was superior to standard therapy in the primary endpoint independently to prior thrombolysis (MW 0.6157; confidence interval (CI) 0.5910–0.6404; P < 0.0001) as well as in all secondary endpoints: mRS at day 21 (MW 0.6065, 95% CI 0.5811–0.6319, P < 0.0001), NIHSS at day 21 (MW 0.5792; 95% CI 0.5576–0.6008; P < 0.0001) and NIHSS at day 90 (MW 0.5781; CI 0.5561–0.6002; P < 0.0001). Additional pre-specified secondary endpoints (proportion of patients with excellent recovery and functional independence) showed moderate superiority for Cerebrolysin. The ordinal MoCA showed superiority for Cerebrolysin in the TP (MW 0.5530; CI 0.5282–0.5778; P < 0.0001) with more pronounced effects in the subgroup with cognitive impairments at baseline (Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) ⩾ 3.3). No differences in safety measures were recorded. The study is notable for its robust data integrity, with valid entries of 90.9% for the primary 90 day mRS assessment with multilevel case mix standardization and an overall dropout rate to the final visit of only 5.7%.

Conclusion::

The results of the C-REGS2 study showed the effectiveness and safety of Cerebrolysin treatment for moderate acute IS in real-world clinical practice.

2025-10-01·International Journal of Stroke

Left atrial occlusion in intracerebral hemorrhage with atrial fibrillation, herpes zoster, and stroke, improving stroke outcomes in China, and Cerebrolysin as a treatment for acute stroke

作者: Markus, Hugh S

项与脑蛋白水解物相关的新闻（医药）

2025-09-11

·PRNewswire

Cerebrolysin IV Therapy Now Available at NexGen Health in Silicon Valley

NexGen Health in San Jose has launched a physician-led Cerebrolysin IV Therapy Program, offering advanced neurological support through a personalized 10-treatment protocol. Designed to aid patients with stroke, traumatic brain injury, cognitive decline, and neurodegenerative diseases, this science-backed therapy enhances neuroplasticity, reduces inflammation, and supports long-term brain health. SAN JOSE, Calif., Sept. 11, 2025 /PRNewswire/ -- NexGen Health, a physician-led regenerative and functional medicine clinic based in San Jose, has announced the official launch of its exclusive Cerebrolysin IV Therapy Program—a cutting-edge neurorecovery protocol designed to support brain health, enhance cognitive function, and provide personalized care for patients managing complex neurological conditions. Continue Reading NexGen Health Led by board-certified physicians specializing in regenerative medicine, physical medicine, interventional pain, and functional medicine, NexGen Health's Cerebrolysin program is centered around a personalized 10-treatment intravenous protocol. Patients are carefully evaluated and monitored throughout the process, which is designed to support recovery from stroke, traumatic brain injury, cognitive decline, and neurodegenerative diseases such as Alzheimer's and Parkinson's. "We are thrilled to bring this groundbreaking neurorecovery therapy to Silicon Valley. This treatment has been so transformative and has worked miracles in the lives of our patients", said Ilbra Petros, Director of Nexgen Health. "Cerebrolysin represents a significant advancement in our ability to support patients with neurological conditions. This therapy offers new possibilities for those seeking to optimize brain health, enhance cognitive function, and recover from injuries where traditional treatments may have shown limited efficacy." Cerebrolysin is a neuropeptide-based therapy containing small proteins and amino acids that mimic naturally occurring neurotrophic factors—the compounds that support neuron growth and survival. Unlike many therapies, Cerebrolysin is capable of crossing the blood-brain barrier, enabling direct access to brain tissue. Its clinical effects include stimulation of neuroplasticity, reduction of neuroinflammation, improved synaptic function, and protection against oxidative stress. Each treatment begins with medical clearance through NexGen Health's clinical team. Once approved, patients receive daily or alternate-day IV infusions of Cerebrolysin over a 10-day period, with treatment sessions typically lasting 20 to 45 minutes. The peptides are rapidly absorbed and transported to brain tissue, where they deliver neuroprotective and regenerative effects through a variety of scientifically validated pathways. The protocol is tailored to patient-specific goals and may be repeated or adjusted based on progress. Many patients report encouraging outcomes within the first cycle, with ongoing improvements in cognitive clarity, focus, motor function, and neurologic resilience. "What sets our Cerebrolysin program apart is our comprehensive, physician-supervised approach," said Dr. James Petros, Founder of NexGen Health. "We take the time to evaluate each patient's unique needs, customize the dosage, and monitor treatment closely. Our goal is to offer safe, science-backed solutions that restore function and improve quality of life." With this launch, NexGen Health further strengthens its position as a leader in innovative biologic and regenerative treatments. The clinic recently introduced Niagen Plus IV Therapy and celebrated a major milestone of 150 five-star Google reviews, underscoring its reputation for patient satisfaction, safety, and results-driven care. Located in the heart of Silicon Valley, NexGen Health provides a wide range of physician-developed programs for neurologic, metabolic, and cellular health—serving patients in San Jose, Los Gatos, Cupertino, and beyond. About NexGen Health Founded by Dr. James Petros in 2021, NexGen Health is a physician-led clinic specializing in functional medicine, regenerative therapies, IV nutrient therapy, hormone optimization, peptide treatments, and advanced wellness programs. The medical team is board-certified in interventional pain and rehabilitation, physical medicine, anti-aging, and longevity care. NexGen Health combines scientific validation, precision diagnostics, and customized protocols to help patients reach their highest level of wellness. To learn more about the Cerebrolysin IV Therapy Program or to schedule a consultation, visit or call (408) 400-2967. Medical clearance through NexGen Health's medical team is required to begin treatment. Media Contact: Ilbra Petros Director, NexGen Health Phone: (408) 400-2967 Website: SOURCE NexGen Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-01-09

·思齐俱乐部

200多个药退出市场！竞争格局生变

1月3日，国家药监局发布《关于注销颠茄磺苄啶片药品注册证书的公告(2025年第2号)》。公告显示，经评价，国家药品监督管理局决定自即日起停止颠茄磺苄啶片在我国的生产、销售、使用，注销药品注册证书。已上市销售的产品，由药品上市许可持有人负责召回，召回产品由所在地省级药品监督管理部门监督销毁或者依法采取其他无害化处理等措施。此次共涉及80个颠茄磺苄啶片被停止生产、销售、使用。涉及企业包括乐声药业石家庄有限公司、江中药业股份有限公司、石家庄四药有限公司、石家庄格瑞药业有限公司、邯郸市柏林药业有限公司、河北永丰药业有限公司、国药集团武汉中联四药药业有限公司、江苏恩华药业股份有限公司、江西鸿烁制药有限责任公司、华北制药河北华诺有限公司、河北恒利集团制药股份有限公司等。此外，2024年12月2日国家药监局还发布关于注销颠茄磺苄啶片等58个药品注册证书的公告(2024年第148号)，其中，11个颠茄磺苄啶片被注销药品注册证书。资料显示，颠茄磺苄啶片为抗菌药物，别名为泻立停，在注销之前可用于治疗痢疾杆菌引起的急慢性菌痢以及其他敏感致病菌引起的肠炎。业内表示，随着颠茄磺苄啶片的退市，相关市场的竞争格局或将发生变化。如在治疗腹泻方面，蒙脱石散等药品也有一定的作用，该药物是止泻药、肠道抗炎/抗感染药重要产品之一。据悉，当前关于“蒙脱石散”的批文有44条，涉及山东罗欣乐康制药、海南先声药业、浙江康恩贝制药等。据悉，根据《中华人民共和国药品管理法》第八十三条等有关规定，经评价，对疗效不确切、不良反应大或者因其他原因危害人体健康的药品，应当注销药品注册证书。已被注销药品注册证书的药品，不得生产或者进口、销售和使用。根据数据统计，在刚刚过去的2024年全年，共有145个药品被注销注册证书。如根据国家药监局关于注销颠茄磺苄啶片等58个药品注册证书的公告(2024年第148号)，除了11个颠茄磺苄啶片被注销药品注册证书外，还包括3个氯沙坦钾片、2个安乃近片、2个苯磺酸氨氯地平片、2个恩替卡韦片、2个复方蛇胆川贝散、2个利福平胶囊等。根据2024年4月11日，国家药监局关于注销泛影葡胺注射液等87个药品注册证书的公告(2024年第43号)，注销注册证书的药品包括泛影葡胺注射液、阿德福韦酯片、氟康唑氯化钠注射液、甘露醇注射液、注射用氨苄西林钠、盐酸小檗碱片、维生素C片、盐酸多西环素片、呋喃唑酮片、碘佛醇注射液、甘精胰岛素注射液、地特胰岛素注射液、盐酸伐地那非片、脑蛋白水解物注射液等。药品注册证书是药品生产、进口、销售和使用的重要法律依据，一旦药品注册证书被注销，该药品就失去了在市场上合法流通的资。根据统计，2024年至今，共有225个药品退出市场。来源：制药网作者：药机君商务合作 130 6172 3098 zakk.cui@siqibest.com 点击阅读原文了解更多

一致性评价

2025-01-08

·思齐俱乐部

225个药品退出市场！相关市场竞争格局或将生变

1月3日，国家药监局发布《关于注销颠茄磺苄啶片药品注册证书的公告(2025年第2号)》。公告显示，经评价，国家药品监督管理局决定自即日起停止颠茄磺苄啶片在我国的生产、销售、使用，注销药品注册证书。已上市销售的产品，由药品上市许可持有人负责召回，召回产品由所在地省级药品监督管理部门监督销毁或者依法采取其他无害化处理等措施。此次共涉及80个颠茄磺苄啶片被停止生产、销售、使用。涉及企业包括乐声药业石家庄有限公司、江中药业股份有限公司、石家庄四药有限公司、石家庄格瑞药业有限公司、邯郸市柏林药业有限公司、河北永丰药业有限公司、国药集团武汉中联四药药业有限公司、江苏恩华药业股份有限公司、江西鸿烁制药有限责任公司、华北制药河北华诺有限公司、河北恒利集团制药股份有限公司等。此外，2024年12月2日国家药监局还发布关于注销颠茄磺苄啶片等58个药品注册证书的公告(2024年第148号)，其中，11个颠茄磺苄啶片被注销药品注册证书。资料显示，颠茄磺苄啶片为抗菌药物，别名为泻立停，在注销之前可用于治疗痢疾杆菌引起的急慢性菌痢以及其他敏感致病菌引起的肠炎。业内表示，随着颠茄磺苄啶片的退市，相关市场的竞争格局或将发生变化。如在治疗腹泻方面，蒙脱石散等药品也有一定的作用，该药物是止泻药、肠道抗炎/抗感染药重要产品之一。据悉，当前关于“蒙脱石散”的批文有44条，涉及山东罗欣乐康制药、海南先声药业、浙江康恩贝制药等。据悉，根据《中华人民共和国药品管理法》第八十三条等有关规定，经评价，对疗效不确切、不良反应大或者因其他原因危害人体健康的药品，应当注销药品注册证书。已被注销药品注册证书的药品，不得生产或者进口、销售和使用。根据数据统计，在刚刚过去的2024年全年，共有145个药品被注销注册证书。如根据国家药监局关于注销颠茄磺苄啶片等58个药品注册证书的公告(2024年第148号)，除了11个颠茄磺苄啶片被注销药品注册证书外，还包括3个氯沙坦钾片、2个安乃近片、2个苯磺酸氨氯地平片、2个恩替卡韦片、2个复方蛇胆川贝散、2个利福平胶囊等。根据2024年4月11日，国家药监局关于注销泛影葡胺注射液等87个药品注册证书的公告(2024年第43号)，注销注册证书的药品包括泛影葡胺注射液、阿德福韦酯片、氟康唑氯化钠注射液、甘露醇注射液、注射用氨苄西林钠、盐酸小檗碱片、维生素C片、盐酸多西环素片、呋喃唑酮片、碘佛醇注射液、甘精胰岛素注射液、地特胰岛素注射液、盐酸伐地那非片、脑蛋白水解物注射液等。药品注册证书是药品生产、进口、销售和使用的重要法律依据，一旦药品注册证书被注销，该药品就失去了在市场上合法流通的资格。根据统计，2024年至今，共有225个药品退出市场。来源：制药网商务合作 130 6172 3098 zakk.cui@siqibest.com 点击阅读原文了解更多

一致性评价医药出海上市批准

100 项与脑蛋白水解物相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	脑蛋白水解物	B05BA04	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
创伤性脑损伤	德国	EBEWE Pharma Ges.m.b.H. Nfg.KG	2000-01-01
血管性痴呆	德国	EBEWE Pharma Ges.m.b.H. Nfg.KG	2000-01-01
阿尔茨海默症	奥地利	EVER Neuro Pharma GmbH	1998-10-28
脑卒中	奥地利	EVER Neuro Pharma GmbH	1998-02-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性缺血性卒中	临床3期	奥地利	EVER Neuro Pharma GmbH	2005-10-01
急性缺血性卒中	临床3期	克罗地亚	EVER Neuro Pharma GmbH	2005-10-01
急性缺血性卒中	临床3期	捷克	EVER Neuro Pharma GmbH	2005-10-01
急性缺血性卒中	临床3期	斯洛伐克	EVER Neuro Pharma GmbH	2005-10-01
急性缺血性卒中	临床3期	斯洛文尼亚	EVER Neuro Pharma GmbH	2005-10-01
常染色体显性遗传病合并皮质下梗死和白质脑病	临床2期	捷克	EVER Neuro Pharma GmbH	2023-11-29
慢性脑血管意外	临床2期	奥地利	EVER Neuro Pharma GmbH	2021-06-25
脑损伤	临床2期	奥地利	EVER Neuro Pharma GmbH	-
脑损伤	临床2期	西班牙	EVER Neuro Pharma GmbH	-
基底动脉闭塞	临床1期	-	EVER Neuro Pharma GmbH	2024-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04904341 (Pubmed \| Transl Stroke Res)	临床3期	急性缺血性卒中追加	50	Cerebrolysin + Mechanical Thrombectomy	願醖鹹獵壓願餘選獵糧(願鬱繭餘築餘製蓋繭範): OR = 2.7 (95% CI, 1.2 ~ 6.1), P-Value = 0.016	积极	2025-05-06
				Cerebrolysin (Historical Controls)
ISRCTN54581790 (ESCAS, Pubmed \| Stroke)	临床4期	急性缺血性卒中	132	Cerebrolysin	願齋願顧構窪積衊餘繭(襯壓簾糧簾鬱顧襯壓蓋) = The Cerebrolysin group also showed significant improvements (higher decreases) in National Institutes of Health Stroke Scale scores compared with the placebo group 構築築艱齋願鹹廠繭憲 (獵鏇製鹽鹽窪網繭繭壓 ) 更多	积极	2025-04-01
				Placebo
NCT04830943 (Pubmed \| Expert Rev Clin Pharmacol)	临床3期	新冠肺炎后遗症	250	Cerebrolysin + olfactory and gustatory trainings	製觸鏇餘窪願網糧衊鬱(鹽窪醖製窪築選繭鹽鹽) = 簾餘壓鹹淵繭顧鹽繭築鑰願糧鑰顧窪鏇壓觸齋 (艱選廠廠鑰鹹獵積觸顧 ) 更多	积极	2023-12-02
NCT02149875 (CTgov)	临床1/2期	急性缺血性卒中	84	Dl-3-n-butylphthalide (Dl-3-n-butylphthalide)	築醖鏇選壓襯積廠鑰積(選蓋鹽選夢繭艱廠構廠) = 範齋遞簾膚糧窪製衊選膚鬱壓窪製鏇壓襯繭廠 (醖憲積選鹽選淵製簾壓, 2.48) 更多	-	2016-05-18
				Cerebrolysin (Cerebrolysin)	築醖鏇選壓襯積廠鑰積(選蓋鹽選夢繭艱廠構廠) = 鬱糧糧築淵觸築繭製壓膚鬱壓窪製鏇壓襯繭廠 (醖憲積選鹽選淵製簾壓, 5.81) 更多
NCT00868283 (Pubmed \| Stroke)	临床4期	急性缺血性卒中	1,070	Cerebrolysin	鬱鏇構齋構餘鬱願蓋網(衊蓋襯願鑰鹽齋鑰選鏇) = 襯艱憲鹽淵鹹鹽憲鏇淵獵襯觸積願築壓餘鹽醖 (衊築衊鏇獵衊繭憲艱醖 )	-	2012-03-01
				Placebo	鬱鏇構齋構餘鬱願蓋網(衊蓋襯願鑰鹽齋鑰選鏇) = 憲蓋願衊選夢築觸淵積獵襯觸積願築壓餘鹽醖 (衊築衊鏇獵衊繭憲艱醖 )
NCT00947531 (VascDem, CTgov)	临床4期	血管性痴呆	242	Cerebrolysin (Cerebrolysin)	淵壓獵淵積襯醖廠簾齋(選衊積鏇簾繭膚積鹽網) = 築餘願壓壓構選網鹽觸遞蓋夢構廠鹽顧憲憲淵 (製膚製壓餘繭獵糧齋網, 7.77) 更多	-	2009-07-28
				0.9% Saline Solution (0.9% Saline Solution)	淵壓獵淵積襯醖廠簾齋(選衊積鏇簾繭膚積鹽網) = 窪夢鹽遞積製衊顧餘醖遞蓋夢構廠鹽顧憲憲淵 (製膚製壓餘繭獵糧齋網, 8.13) 更多